CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity
(1) Naessens F (2) Demuynck R (3) Vershinina O (4) Efimova I (5) Saviuk M (6) De Smet G (7) Mishchenko TA (8) Vedunova MV (9) Krysko O (10) Catanzaro E (11) Krysko DV
Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade
(1) Jin C (2) Zhang Y (3) Li B (4) Gao T (5) Wang B (6) Hua P
(1) Jin C (2) Zhang Y (3) Li B (4) Gao T (5) Wang B (6) Hua P
Author Info: (1) Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, 130022, China. (2) Department of Thoracic Surgery, The Second Hospital of Ji
Author Info: (1) Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, 130022, China. (2) Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, 130022, China. (3) Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, 130022, China. (4) College of Clinical Medicine, Jiamusi University, Jiamusi, Heilongjiang Province, 154007, China. (5) Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, 130022, China. (6) Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, 130022, China.
Citation: Mater Today Bio 2024 Aug 27:101136 Epub06/22/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/39015802
Beyond Cytotoxic Potency: Disposition Features Required to Design ADC Payload
(1) Sun H (2) Wienkers LC (3) Lee A
(1) Sun H (2) Wienkers LC (3) Lee A
Author Info: (1) Clinical Pharmacology and Translational Sciences, Pfizer Oncology Division, Pfizer, Inc., Bothell, Washington 98021. (2) Clinical Pharmacology and Translational Sciences, Pfize
Author Info: (1) Clinical Pharmacology and Translational Sciences, Pfizer Oncology Division, Pfizer, Inc., Bothell, Washington 98021. (2) Clinical Pharmacology and Translational Sciences, Pfizer Oncology Division, Pfizer, Inc., Bothell, Washington 98021. (3) Clinical Pharmacology and Translational Sciences, Pfizer Oncology Division, Pfizer, Inc., Bothell, Washington 98021.
Citation: Xenobiotica 2024 Jul 17 1-25 Epub07/17/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/39017706
Tags:
Crosstalk between Circadian Rhythm Dysregulation and Tumorigenesis, Tumor Metabolism and Tumor Immune Response
(1) Zhu Y (2) Zheng Y (3) Dai R (4) Gu X
(1) Zhu Y (2) Zheng Y (3) Dai R (4) Gu X
Author Info: (1) Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, China. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. Cancer
Author Info: (1) Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, China. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China. Institute of Pathology, Fudan University, Shanghai, China. (2) Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China. (3) School of Medicine, Southeast University, Nanjing, China. (4) Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Citation: Aging Dis 2024 Jul 2 Epub07/02/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/39012661
Tags:
Chronological Management of Adjuvant Effect for Optimized mRNA Vaccine Inspired by Natural Virus Infection
(1) Lou Z (2) Shi Y (3) Guo X (4) Jin Z (5) Huang J (6) Hu Y (7) Liu X (8) Zhu J (9) Kuang R (10) You J
(1) Lou Z (2) Shi Y (3) Guo X (4) Jin Z (5) Huang J (6) Hu Y (7) Liu X (8) Zhu J (9) Kuang R (10) You J
Author Info: (1) College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China. (2) College of Pharmaceutical Sciences, Zhejiang Universit
Author Info: (1) College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China. (2) College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China. (3) College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China. (4) College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China. (5) College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China. (6) College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China. (7) College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China. (8) Department of Ultrasound, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P. R. China. (9) Zhejiang Institute for Food and Drug Control, 325 Pingle Street, Hangzhou, Zhejiang 310004, P. R. China. (10) College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, 79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang 310006, P. R. China. The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou, Zhejiang 310006, P. R. China. Jinhua Institute of Zhejiang University, 498 Yiwu Street, Jinhua, Zhejiang 321299, P. R. China.
Citation: ACS Nano 2024 Jul 16 Epub07/16/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/39011561
Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy
(1) Elkrief A (2) Mndez-Salazar EO (3) Maillou J (4) Vanderbilt CM (5) Gogia P (6) Desilets A (7) Messaoudene M (8) Kelly D (9) Ladanyi M (10) Hellmann MD (11) Zitvogel L (12) Rudin CM (13) Routy B (14) Derosa L (15) Schoenfeld AJ
(1) Elkrief A (2) Mndez-Salazar EO (3) Maillou J (4) Vanderbilt CM (5) Gogia P (6) Desilets A (7) Messaoudene M (8) Kelly D (9) Ladanyi M (10) Hellmann MD (11) Zitvogel L (12) Rudin CM (13) Routy B (14) Derosa L (15) Schoenfeld AJ
Author Info: (1) Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. arielle.elkrief@umontreal.ca. Human Oncology and Pathogenesis Program, Memorial Sloan Ketter
Author Info: (1) Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. arielle.elkrief@umontreal.ca. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. arielle.elkrief@umontreal.ca. Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. arielle.elkrief@umontreal.ca. University of Montreal Research Center (CR-CHUM), Montreal, QC, Canada. arielle.elkrief@umontreal.ca. Department of Hematology-Oncology, Centre Hospitalier de l'Universit de Montral (CHUM), Montreal, QC, Canada. arielle.elkrief@umontreal.ca. (2) University of Montreal Research Center (CR-CHUM), Montreal, QC, Canada. (3) University of Montreal Research Center (CR-CHUM), Montreal, QC, Canada. (4) Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. (5) Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. (6) Department of Hematology-Oncology, Centre Hospitalier de l'Universit de Montral (CHUM), Montreal, QC, Canada. (7) University of Montreal Research Center (CR-CHUM), Montreal, QC, Canada. (8) Informatics Systems, Memorial Sloan Kettering Cancer, New York, NY, USA. (9) Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. (10) Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Department of Medicine, Weill Cornell Medical College, New York, NY, USA. (11) INSERM U1015, Gustave Roussy Cancer Campus, Universit Paris-Saclay, Villejuif, France. (12) Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Department of Medicine, Weill Cornell Medical College, New York, NY, USA. (13) University of Montreal Research Center (CR-CHUM), Montreal, QC, Canada. Department of Hematology-Oncology, Centre Hospitalier de l'Universit de Montral (CHUM), Montreal, QC, Canada. (14) INSERM U1015, Gustave Roussy Cancer Campus, Universit Paris-Saclay, Villejuif, France. (15) Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. schoenfa@mskcc.org. Department of Medicine, Weill Cornell Medical College, New York, NY, USA. schoenfa@mskcc.org.
Citation: NPJ Precis Oncol 2024 Jul 16 8:143 Epub07/16/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/39014160
Tags:
Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell Lymphoma
(1) Park J (2) Palomba ML (3) Perica K (4) Devlin S (5) Shah G (6) Dahi P (7) Lin R (8) Salles G (9) Scordo M (10) Nath K (11) Valtis Y (12) Lynch A (13) Cathcart E (14) Zhang H (15) Schder H (16) Leithner D (17) Liotta K (18) Yu A (19) Stocker K (20) Li J (21) Dey A (22) Sellner L (23) Singh R (24) Sundaresan V (25) Zhao F (26) Mansilla-Soto J (27) He C (28) Meyerson J (29) Hosszu K (30) McAvoy D (31) Wang X (32) Riviere I (33) Sadelain M
(1) Park J (2) Palomba ML (3) Perica K (4) Devlin S (5) Shah G (6) Dahi P (7) Lin R (8) Salles G (9) Scordo M (10) Nath K (11) Valtis Y (12) Lynch A (13) Cathcart E (14) Zhang H (15) Schder H (16) Leithner D (17) Liotta K (18) Yu A (19) Stocker K (20) Li J (21) Dey A (22) Sellner L (23) Singh R (24) Sundaresan V (25) Zhao F (26) Mansilla-Soto J (27) He C (28) Meyerson J (29) Hosszu K (30) McAvoy D (31) Wang X (32) Riviere I (33) Sadelain M
Author Info: (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33)
Author Info: (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33)
Citation: Res Sq 2024 Jul 2 Epub07/02/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/39011120
Adeno-associated virus delivered CXCL9 sensitizes glioblastoma to anti-PD-1 immune checkpoint blockade
(1) von Roemeling CA (2) Patel JA (3) Carpenter SL (4) Yegorov O (5) Yang C (6) Bhatia A (7) Doonan BP (8) Russell R (9) Trivedi VS (10) Klippel K (11) Ryu DH (12) Grippin A (13) Futch HS (14) Ran Y (15) Hoang-Minh LB (16) Weidert FL (17) Golde TE (18) Mitchell DA
(1) von Roemeling CA (2) Patel JA (3) Carpenter SL (4) Yegorov O (5) Yang C (6) Bhatia A (7) Doonan BP (8) Russell R (9) Trivedi VS (10) Klippel K (11) Ryu DH (12) Grippin A (13) Futch HS (14) Ran Y (15) Hoang-Minh LB (16) Weidert FL (17) Golde TE (18) Mitchell DA
Author Info: (1) Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA. christina.vonroemeling@neurosurgery.ufl.edu. Preston A. Wells, Jr. Center for Brain Tu
Author Info: (1) Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA. christina.vonroemeling@neurosurgery.ufl.edu. Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA. christina.vonroemeling@neurosurgery.ufl.edu. (2) Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA. Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA. (3) Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA. Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA. (4) Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA. Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA. (5) Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA. Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA. (6) Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA. Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA. (7) Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA. Department of Medicine, Hematology and Oncology, University of Florida, Gainesville, FL, USA. (8) Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA. Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA. (9) Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA. Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA. (10) Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA. Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA. (11) Goizueta Brain Health Institute, Emory University School of Medicine, Atlanta, GA, USA. (12) Department of Radiation Oncology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA. (13) Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA. (14) Goizueta Brain Health Institute, Emory University School of Medicine, Atlanta, GA, USA. (15) Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA. Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA. (16) Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA. Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA. (17) Goizueta Brain Health Institute, Emory University School of Medicine, Atlanta, GA, USA. (18) Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA. duane.mitchell@neurosurgery.ufl.edu. Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA. duane.mitchell@neurosurgery.ufl.edu.
Citation: Nat Commun 2024 Jul 12 15:5871 Epub07/12/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38997283
Dendritic cells steering antigen and leukocyte traffic in lymph nodes
(1) Dotta E (2) Maciola AK (3) Baccega T (4) Pasqual G
(1) Dotta E (2) Maciola AK (3) Baccega T (4) Pasqual G
Author Info: (1) Laboratory of Synthetic Immunology, Oncology and Immunology Section, Department of Surgery Oncology and Gastroenterology, University of Padua, Italy. (2) Laboratory of Syntheti
Author Info: (1) Laboratory of Synthetic Immunology, Oncology and Immunology Section, Department of Surgery Oncology and Gastroenterology, University of Padua, Italy. (2) Laboratory of Synthetic Immunology, Oncology and Immunology Section, Department of Surgery Oncology and Gastroenterology, University of Padua, Italy. (3) Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. (4) Laboratory of Synthetic Immunology, Oncology and Immunology Section, Department of Surgery Oncology and Gastroenterology, University of Padua, Italy. Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Citation: FEBS Lett 2024 Jul 12 Epub07/12/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38997244
Tags:
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial
(1) Ray-Coquard IL (2) Savoye AM (3) Schiffler C (4) Mouret-Reynier MA (5) Derbel O (6) Kalbacher E (7) LeHeurteur M (8) Martinez A (9) Cornila C (10) Martinez M (11) Bengrine Lefevre L (12) Priou F (13) Cloarec N (14) Venat L (15) Selle F (16) Berton D (17) Collard O (18) Coquan E (19) Le Saux O (20) Treilleux I (21) Gouerant S (22) Angelergues A (23) Joly F (24) Tredan O
(1) Ray-Coquard IL (2) Savoye AM (3) Schiffler C (4) Mouret-Reynier MA (5) Derbel O (6) Kalbacher E (7) LeHeurteur M (8) Martinez A (9) Cornila C (10) Martinez M (11) Bengrine Lefevre L (12) Priou F (13) Cloarec N (14) Venat L (15) Selle F (16) Berton D (17) Collard O (18) Coquan E (19) Le Saux O (20) Treilleux I (21) Gouerant S (22) Angelergues A (23) Joly F (24) Tredan O
Author Info: (1) Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Centre Lon Brard, University Claude Bernard, Lyon, France. isabelle.ray-coquard@lyon.unicance
Author Info: (1) Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Centre Lon Brard, University Claude Bernard, Lyon, France. isabelle.ray-coquard@lyon.unicancer.fr. (2) GINECO and Institut Jean Godinot, Reims, France. (3) Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Centre Lon Brard, University Claude Bernard, Lyon, France. (4) GINECO and Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France. (5) GINECO and Institut de Cancrologie, Hpital Priv Jean Mermoz, Lyon, France. (6) GINECO and Centre Hospitalier Universitaire Jean Minjoz, Besanon, France. (7) GINECO and Medical Oncology Department, Centre Henri-Becquerel, Rouen, France. (8) GINECO and Institut Claudius Rgaud, Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole, Toulouse, France. (9) GINECO and Centre Hospitalier Rgional d'Orlans, Orleans, France. (10) GINECO and Clinique Pasteur, Toulouse, France. (11) GINECO and Centre Georges-Franois Leclerc, Dijon, France. (12) GINECO and Centre Hospitalier Dpartemental Vende, La Roche-Sur-Yon, France. (13) GINECO and Centre Hospitalier Henri Duffaut d'Avignon, Avignon, France. (14) GINECO and Centre Hospitalier Universitaire Dupuytren, Limoges, France. (15) GINECO and Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France. (16) GINECO and Institut de Cancrologie de l'Ouest, Centre Ren Gauducheau, Saint-Herblain, France. (17) GINECO and Institut de Cancrologie de la Loire, Saint-Priest-en-Jarez, France. Center of Medical Oncology, Hpital Priv de la Loire, Saint-Etienne, France. (18) GINECO and Department of Medical Oncology, Centre Franois Baclesse, University Caen Normandie, Caen, France. (19) Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Centre Lon Brard, University Claude Bernard, Lyon, France. Cancer Research Center of Lyon (CRCL), UMR INSERM 1052, Centre Lon Brard, CNRS 5286, Lyon, France. (20) Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Centre Lon Brard, University Claude Bernard, Lyon, France. (21) GINECO and Medical Oncology Department, Centre Henri-Becquerel, Rouen, France. (22) GINECO and Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France. (23) GINECO and Department of Medical Oncology, Centre Franois Baclesse, University Caen Normandie, Caen, France. (24) GINECO and Department of Medical Oncology, Centre Lon Brard, Lyon, France.
Citation: Nat Commun 2024 Jul 16 15:5931 Epub07/16/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/39013870